Where Do We Stand with JAK Inhibitors in Development?

Published on

Topics include: Treatment

Are there additional JAK inhibitors in development? Dr. Claire Harrison, a leading MPN researcher, discusses JAK inhibitor drugs currently in clinical trials. Dr. Harrison reviews encouraging early data and explains what it could mean for patients.

Made possible through an educational grant from the Patient Empowerment Network.

View more programs featuring

Transcript

But there are other JAK inhibitors which are available about which there are important information at this meeting.  None of these drugs have completed Phase III studies, unfortunately.  Fedratinib was at the point where it had completed Phase III study, was in the process of completing a study for patients as a second-line drug after ruxolitinib, showed promise, so it demonstrates there is a need, as you rightly say. 

So the other drugs that we see discussed at this meeting are pacritinib, SB1518.  There's nice data with Serge and others showing long?term data with this agent, showing again there is little gastrointestinal toxicity.  This might be a strong candidate drug for patients with lower blood counts and producing quite striking clinical benefit.  As you probably know, the PERSIST?1 study is ongoing with pacritinib. And PERSIST?2, which allows us to enroll patients who previously had a JAK inhibitor, will be opening shortly. 

Other drugs, momelotinib, previously known as CYT387, an update presented by colleagues from the Mayo Clinic again showing benefits for spleen symptoms and this intriguing story of anemia response.  And we've very much hope to be able to launch a Phase III study with that drug, which is likely it seems to be perhaps a head?to?head study with ruxolitinib.  I think this is very important and a very laudable approach for patients in particular, so we won't be saying, well, you can have this JAK inhibitor, or you can have a sugar pill, or you can have best available therapy, because frankly that's not ethical anymore.  So we will be comparing, I think, in the future likely at least first line these drugs against ruxolitinib.  So momelotinib, I think, is the one to watch. 

 The BMS drug, also interesting.  And the Lilly drug also presenting data at this meeting.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

 

Related Programs

Understanding the Evolving MPN Treatment Landscape

Dr. Ruben Mesa, dedicated MPN researcher and deputy director of the Mayo Clinic Cancer Center, explores the evolving MPN treatment landscape.

Published:

Advances in Understanding and Treating MPNs

Dr. Srdan Verstovsek, a world-renowned researcher from MD Anderson Cancer Center, explores what he describes as "unprecedented developments" in the understanding of myeloproliferative neoplasms (MPNs) and how new research could lead to more effective treatment.

Published:

Exciting Data on Developing Drugs for Myelofibrosis

Over the past year, there has been continued progress in improving treatments for myelofibrosis. Watch now as Dr. Claire Harrison shares updated news from the Comfort II study, including how patients are responding to the treatment regimen with few side effects.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on September 2, 2014